Moleculin Biotech Inc MBRX

NAS: MBRX | ISIN: US60855D1019 14/11/2024

3,090 USD (+23,11%)

(+23,11%) 14/11/2024

Grafiek Moleculin Biotech Inc

Grafiek Moleculin Biotech Inc

1 dag1d 23,11%
1 week1w 21,18%
1 maand1m 32,62%
3 maanden3m 38,57%
6 maanden6m -37,20%
1 jaar1j 442,11%
5 jaar5j -50,95%

Moleculin Biotech Inc in het nieuws

Toon enkel gratis nieuws

9 september 2024 · Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma · Persbericht

3 september 2024 · Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

26 augustus 2024 · Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar · Persbericht

19 augustus 2024 · Moleculin Announces Closing of up to $16.5 Million Public Offering · Persbericht

16 augustus 2024 · Moleculin Announces Pricing of up to $16.5 Million Public Offering · Persbericht

14 augustus 2024 · Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

5 augustus 2024 · Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET · Persbericht

1 augustus 2024 · Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial · Persbericht

10 juli 2024 · Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML · Persbericht

14 juni 2024 · Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial · Persbericht

Profiel Moleculin Biotech Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.moleculin.com

Hoofdzetel: Houston, Texas Verenigde Staten

Werknemers: 20

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe